Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase

被引:380
|
作者
Freitas, C [1 ]
Müller, RH [1 ]
机构
[1] Free Univ Berlin, Dept Pharmaceut Biopharmaceut & Biotechnol, D-12196 Berlin, Germany
关键词
solid lipid nanoparticles; long-term stability; differential scanning calorimetry; polymorphism;
D O I
10.1016/S0939-6411(98)00074-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aqueous dispersions of solid lipid nanoparticles (SLN(TM)) are usually physically stable for more than 3 years. However, in some systems gelation occurred leading to solid gels due to an unknown mechanism. To elucidate this mechanism, Compritol(R) SLN were stored at different temperatures, varying light exposure, in different packing materials and stressed by shear forces in short-term tests and a long-term study of 3 years. The SLN were analyzed by differential scanning calorimetry and sizing techniques. After production by hot homogenization of the melted lipid, the Compritol(R) SLN crystallize in a mixture of stable beta' with unstable polymorphs (alpha, sub alpha). The destabilizing factors light, temperature and shear forces cause a distinct increase in the recrystallization index by transformation of the lipid to the beta' modification being accompanied by gel formation. Physically stable SLN remain as a mixture of modifications, increase in crystallinity index during storage is slow and crystallization occurs mainly in unstable modifications. From this, stabilization of physically critical SLN dispersions seems possible by inhibition of the transformation of the lipid to the stable modification. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:125 / 132
页数:8
相关论文
共 50 条
  • [1] Chemical stability of the lipid matrices of solid lipid nanoparticles (SLN)-development of an analytical method and determination of long-term stability
    Radomska, A
    Dobrucki, R
    Müller, RH
    PHARMAZIE, 1999, 54 (12): : 903 - 909
  • [2] Optimization of the lyophilization process for long-term stability of solid-lipid nanoparticles
    Howard, Melissa D.
    Lu, Xiuling
    Jay, Michael
    Dziubla, Thomas D.
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2012, 38 (10) : 1270 - 1279
  • [3] Incorporation of cyclosporin A in solid lipid nanoparticles (SLN)
    Ugazio, E
    Cavalli, R
    Gasco, MR
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 241 (02) : 341 - 344
  • [4] Cosmetic applications for solid lipid nanoparticles (SLN)
    Wissing, SA
    Müller, RH
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 254 (01) : 65 - 68
  • [5] Encapsulation of retinoids in solid lipid nanoparticles (SLN®)
    Jenning, V
    Gohla, SH
    JOURNAL OF MICROENCAPSULATION, 2001, 18 (02) : 149 - 158
  • [6] Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy
    del Pozo-Rodriguez, A.
    Solinis, M. A.
    Gascon, A. R.
    Pedraz, J. L.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 71 (02) : 181 - 189
  • [7] Investigations on the occlusive properties of solid lipid nanoparticles (SLN)
    Wissing, SA
    Lippacher, A
    Müller, RH
    JOURNAL OF COSMETIC SCIENCE, 2001, 52 (05): : 313 - 324
  • [8] Effect of Surfactant on Characteristics of Solid Lipid Nanoparticles (SLN)
    Kullavadee, Karn-orachai
    Uracha, Ruktanonchai
    Smith, Siwaporn Meejoo
    NANOMATERIALS: SYNTHESIS AND CHARACTERIZATION, 2012, 364 : 313 - +
  • [9] Optimization of the Conditions of Solid Lipid Nanoparticles (SLN) Synthesis
    Musielak, Ewelina
    Feliczak-Guzik, Agnieszka
    Nowak, Izabela
    MOLECULES, 2022, 27 (07):
  • [10] Solid lipid nanoparticles (SLN) for intravenous drug delivery
    Muller, RH
    zurMuhlen, A
    Freitas, C
    Mehnert, W
    23RD INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS, 1996 PROCEEDINGS, 1996, : 184 - 185